SEARCH:   Advanced

Blood, 1 October 2004, Vol. 104, No. 7, pp. 1995-1999. Prepublished online as a Blood First Edition Paper on June 8, 2004; DOI 10.1182/blood-2004-04-1550. This Article Full Text (PDF) All Versions of this Article: 2004-04-1550v1 104/7/1995    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lo-Coco, F. Articles by Mandelli, F. Search for Related Content PubMed PubMed Citation Articles by Lo-Coco, F. Articles by Mandelli, F. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 26, 2004 Accepted May 30, 2004 Gentuzumab ozogamicin (''mylotarg'') as a single agent for molecularly relapsed acute promyelocytic leukemia Francesco Lo-Coco*, Giuseppe Cimino, Massimo Breccia, Nelida I Noguera, Daniela Diverio, Erica Finolezzi, Enrico M Pogliani, Eros Di Bona, Concetta Micalizzi, Mariagrazia Kropp, Adriano Venditti, Agostino Tafuri, and Franco Mandelli Biopathology, University Tor Vergata, Roma, Italy Cellular Biotechnology and Hematology, University La Sapienza, Roma, Italy Medicine, Ospedale S. Gerardo, Milano-Monza, Italy Terapia Cellulare ed Ematologia, Ospedale S. Bortolo, Vicenza, Italy Ematologia ed Oncologia Pediatrica, Ospedale G. Gaslini, Genova, Italy Ospedale Regionale, Catanzaro, Italy * Corresponding author; email: francesco.lo.coco{at}uniroma2.it. The anti-CD33 antibody-calicheamicin conjugate gentuzumab-ozogamicin (GO) was used as a single agent to treat 16 patients with acute promyelocytic leukemia relapsed at the molecular level. Of these, 8 patients were in first, 5 in second, 2 in third and 1 in fourth relapse. GO was administered at 6 mg/m2 for 2 doses and patients achieving a new molecular remission (MR, i.e. negativization of the RT-PCR test for PML/RAR) received a final third dose. MR was obtained in 9/11 (91%) patients tested after 2 doses and in 13/13 (100%) patients tested after the third dose. Of the 3 remaining patients, 1 achieved MR after a single GO administration and received no further therapy due to hepatic toxicity, and 2 showed disease progression during treatment (morphological relapse). Quantitative RT-PCR studies showed in responding patients a dramatic decline (greater than 2 logs) of the hybrid PML/RAR transcript after the first GO dose. Of the 14 responders, 7 patients remained in sustained MR for a median time of 15 mos. (range 7-31 mos.) and received no further therapy, while 7 relapsed at 3-15 mos. GO was administered again in 2 relapsing patients and both obtained a new MR. These data indicate that: i) GO is highly effective as single treatment for patients with molecularly relapsed APL including those with very advanced disease; ii) Further treatment should be used in these patients after MR in order to obtain prolonged molecular response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Acute promyelocytic leukemia: a target for preemptive strike? Dan Douer Blood 2004 104: 1913-1914. [Full Text] [PDF] This article has been cited by other articles: C. Kelaidi, S. Chevret, S. De Botton, E. Raffoux, A. Guerci, X. Thomas, A. Pigneux, T. Lamy, F. Rigal-Huguet, S. Meyer-Monard, et al. Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience J. Clin. Oncol., June 1, 2009; 27(16): 2668 - 2676. [Abstract] [Full Text] [PDF] M. A. Sanz, D. Grimwade, M. S. Tallman, B. Lowenberg, P. Fenaux, E. H. Estey, T. Naoe, E. Lengfelder, T. Buchner, H. Dohner, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, February 26, 2009; 113(9): 1875 - 1891. [Abstract] [Full Text] [PDF] F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, et al. Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin J. Clin. Oncol., February 1, 2009; 27(4): 504 - 510. [Abstract] [Full Text] [PDF] Z.-Y. Wang and Z. Chen Acute promyelocytic leukemia: from highly fatal to highly curable Blood, March 1, 2008; 111(5): 2505 - 2515. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] M. Breccia, G. Cimino, D. Diverio, F. Gentilini, F. Mandelli, and F. L. Coco Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia Haematologica, September 1, 2007; 92(9): 1273 - 1274. [Abstract] [Full Text] [PDF] N. Asou, Y. Kishimoto, H. Kiyoi, M. Okada, Y. Kawai, M. Tsuzuki, K. Horikawa, M. Matsuda, K. Shinagawa, T. Kobayashi, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study Blood, July 1, 2007; 110(1): 59 - 66. [Abstract] [Full Text] [PDF] J. A. Pollard, T. A. Alonzo, R. B. Gerbing, W. G. Woods, B. J. Lange, D. A. Sweetser, J. P. Radich, I. D. Bernstein, and S. Meshinchi FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia Blood, October 15, 2006; 108(8): 2764 - 2769. [Abstract] [Full Text] [PDF] M. S. Tallman From rags to riches Blood, May 1, 2006; 107(9): 3425 - 3425. [Full Text] [PDF] E. Estey, G. Garcia-Manero, A. Ferrajoli, S. Faderl, S. Verstovsek, D. Jones, and H. Kantarjian Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood, May 1, 2006; 107(9): 3469 - 3473. [Abstract] [Full Text] [PDF] A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF] M. A. Sanz Treatment of Acute Promyelocytic Leukemia Hematology, January 1, 2006; 2006(1): 147 - 155. [Abstract] [Full Text] [PDF] F. Lo-Coco and E. Ammatuna The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment Hematology, January 1, 2006; 2006(1): 156 - 161. [Abstract] [Full Text] [PDF] R. E. Gale, R. Hills, A. R. Pizzey, P. D. Kottaridis, D. Swirsky, A. F. Gilkes, E. Nugent, K. I. Mills, K. Wheatley, E. Solomon, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia Blood, December 1, 2005; 106(12): 3768 - 3776. [Abstract] [Full Text] [PDF] J. Feusner APL treatment Italian style: is this the cure? Blood, July 15, 2005; 106(2): 392 - 393. [Full Text] [PDF] D. H. Nguyen, P. Tangvoranuntakul, and A. Varki Effects of Natural Human Antibodies against a Nonhuman Sialic Acid That Metabolically Incorporates into Activated and Malignant Immune Cells J. Immunol., July 1, 2005; 175(1): 228 - 236. [Abstract] [Full Text] [PDF] M. S. Tallman New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Hematology, January 1, 2005; 2005(1): 143 - 150. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020